Retention and expansion for Series B companies: scaling without breaking for healthcare and life sciences in the United Kingdom

This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in the United Kingdom. In this market, UK buyers reward understatement, credible references, and a pitch that respects their time, so the way you install retention and expansion has to be shaped to that reality from day one.

Series B is the stress test for retention and expansion. What worked at fifteen people fails at fifty unless the operating rhythm is deliberate.

The Series B move is to separate the model owner from the operators. One senior human owns strategy, gross and net revenue retention, and the weekly review; a small team runs the machine.

Add a second geography or segment only when the first one is producing a defensible number for two full quarters. Not before.

Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in the United Kingdom it is compounded by the fact that credibility and reference base, not tooling is what actually gates growth. Retention and expansion is only useful here when it is pointed at both constraints at once.

Governance appears at Series B — that is fine, provided it accelerates rather than slows. The test is whether reviews still make decisions or just distribute updates.

The Series B failure mode of retention and expansion is treating CS as a support cost centre, amplified by headcount. Fix the root cause; do not paper over it with more people.

Compensation begins to matter now. Pay operators on gross and net revenue retention outcomes, not on effort. Effort-based comp at Series B produces theatre.

A well-run retention and expansion function at Series B is the moat that survives to Series C. Companies that skip this discipline burn through raises trying to buy it back.

Concretely for healthcare and life sciences in the United Kingdom: the healthcare teams that install this get past procurement instead of dying in it, and a single London-anchored win reshapes an entire year of UK pipeline. That is the reason it is worth installing retention and expansion deliberately for this market rather than importing a playbook designed for somewhere else.